Paratek Pharmaceuticals to acquire Optinose in $330M transaction
Paratek Pharmaceuticals (PRTK) and Optinose (OPTN) announced they have entered into a definitive merger agreement under which Paratek will ...
Optinose to be acquired by Boston-based Paratek Pharmaceuticals in potential $330M deal
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Fierce Pharma10d
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
Yahoo Finance11d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under ...
OptiNose climbs after take-private deal with Paratek Pharma
OptiNose (NASDAQ:OPTN) stock surges 61% as Paratek Pharmaceuticals agrees to a $330M acquisition. Read mroe here.
The National Law Review12d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market Acquisition advances ...
Eagle-Tribune12d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion ...
BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under ...
The Bakersfield Californian11d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion ...
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek’s visio ...